CL2020003214A1 - Nuevos derivados de isoxazolil éter como pam de gaba a alfa5 - Google Patents

Nuevos derivados de isoxazolil éter como pam de gaba a alfa5

Info

Publication number
CL2020003214A1
CL2020003214A1 CL2020003214A CL2020003214A CL2020003214A1 CL 2020003214 A1 CL2020003214 A1 CL 2020003214A1 CL 2020003214 A CL2020003214 A CL 2020003214A CL 2020003214 A CL2020003214 A CL 2020003214A CL 2020003214 A1 CL2020003214 A1 CL 2020003214A1
Authority
CL
Chile
Prior art keywords
alfa5
gaba
pam
new derivatives
isoxazolyl
Prior art date
Application number
CL2020003214A
Other languages
English (en)
Inventor
Emmanuel Pinard
Giuseppe Cecere
Zbinden Katrin Groebke
Maria-Clemencia Hernandez
Henner Knust
Andreas Koblet
Morales Andres Miguel Olivares
Angélique Patiny-Adam
Valerie Runtz-Schmitt
Sandra Steiner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2020003214A1 publication Critical patent/CL2020003214A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención proporciona nuevos compuestos que tienen la Fórmula general (I) o (II); en donde R2, R3, R5, R99, W, Y y Z son como se describen en la presente descripción, composiciones que incluyen los compuestos y métodos de uso de los compuestos.
CL2020003214A 2018-06-13 2020-12-10 Nuevos derivados de isoxazolil éter como pam de gaba a alfa5 CL2020003214A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18177522 2018-06-13
EP18177825 2018-06-14

Publications (1)

Publication Number Publication Date
CL2020003214A1 true CL2020003214A1 (es) 2021-05-07

Family

ID=66776367

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020003214A CL2020003214A1 (es) 2018-06-13 2020-12-10 Nuevos derivados de isoxazolil éter como pam de gaba a alfa5

Country Status (18)

Country Link
US (1) US11840528B2 (es)
EP (1) EP3807269A1 (es)
JP (1) JP7478676B2 (es)
KR (1) KR20210021019A (es)
CN (1) CN112424196A (es)
AU (1) AU2019286312B2 (es)
BR (1) BR112020025355A2 (es)
CA (1) CA3102101A1 (es)
CL (1) CL2020003214A1 (es)
CR (1) CR20200610A (es)
IL (1) IL279266B2 (es)
MA (1) MA52868A (es)
MX (1) MX2020013518A (es)
PE (1) PE20210555A1 (es)
PH (1) PH12020500674A1 (es)
SG (1) SG11202012200QA (es)
TW (1) TWI816812B (es)
WO (1) WO2019238633A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12649738B2 (en) 2020-03-26 2026-06-09 Richter Gedeon Nyrt. 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine derivatives as GABAA α5 receptor modulators
TWI901650B (zh) 2020-03-26 2025-10-21 匈牙利商羅特格登公司 啶及吡啶并〔３，４－ｃ〕嗒衍生物
EP4149933B1 (en) * 2020-05-13 2024-06-12 F. Hoffmann-La Roche AG New triazolyl derivatives as gaba a alpha5 pam
HU231691B1 (hu) 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
WO2026009854A1 (ja) * 2024-07-01 2026-01-08 日本たばこ産業株式会社 ピリダジノン化合物及びその医薬用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2682301A1 (en) * 2007-04-18 2008-10-30 Astrazeneca Ab Xanthine compounds having a positive allosteric gabab receptor modulator effect
JP5301557B2 (ja) * 2007-12-04 2013-09-25 エフ．ホフマン−ラ ロシュ アーゲー イソオキサゾロ−ピリジン誘導体
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
AU2009249186B2 (en) 2008-05-19 2014-05-22 Sunovion Pharmaceuticals Inc. Imidazo [1, 2-a] pyridine compounds as GABA-A receptor modulators
BRPI1014454A2 (pt) * 2009-05-05 2016-04-05 Hoffmann La Roche derivados de isoxazol-pirazol
US8785435B2 (en) 2011-10-20 2014-07-22 Hoffmann-La Roche Inc. Solid forms
US8604062B2 (en) 2011-10-20 2013-12-10 Hoffman-La Roche Inc. Process for the preparation of isoxazolyl-methoxy nicotinic acids
MA48594B1 (fr) 2016-12-08 2022-05-31 Hoffmann La Roche Nouveaux dérivés d'éther d'isoxazolyle en tant que pam alpha5 gaba a

Also Published As

Publication number Publication date
EP3807269A1 (en) 2021-04-21
KR20210021019A (ko) 2021-02-24
CR20200610A (es) 2021-02-05
US11840528B2 (en) 2023-12-12
CN112424196A (zh) 2021-02-26
IL279266B2 (en) 2024-03-01
IL279266A (en) 2021-01-31
JP7478676B2 (ja) 2024-05-07
TW202016106A (zh) 2020-05-01
JP2021527099A (ja) 2021-10-11
MX2020013518A (es) 2021-02-26
TWI816812B (zh) 2023-10-01
US20210094945A1 (en) 2021-04-01
WO2019238633A1 (en) 2019-12-19
PE20210555A1 (es) 2021-03-17
IL279266B1 (en) 2023-11-01
CA3102101A1 (en) 2019-12-19
SG11202012200QA (en) 2021-01-28
AU2019286312A1 (en) 2021-01-07
AU2019286312B2 (en) 2023-08-17
MA52868A (fr) 2021-04-21
BR112020025355A2 (pt) 2021-03-09
PH12020500674A1 (en) 2021-06-07

Similar Documents

Publication Publication Date Title
CO2021007056A2 (es) Nuevos compuestos heterocíclicos
CL2021003373A1 (es) Nuevos inhibidores de egfr
CL2021003190A1 (es) Inhibidores de tead y usos de los mismos
BR112021024224A2 (pt) Inibidores de tead e usos dos mesmos
CR20190268A (es) Nuevos deribados de isoxazolil éter como pam de gaba a alfa5
MX2022007841A (es) Degradadores del regulador dependiente de actina asociado a la matriz relacionado con el complejo switch/sacarosa no fermentable de la subfamilia a de la cromatina (smarca)y usos de los mismos.
CO2019009373A2 (es) Compuestos heterocíclicos útiles como inhibidores duales de atx/ca.
PH12021500014A1 (en) Fused ring compounds
CO2022002336A2 (es) Compuestos heterocíclicos
CO2020009567A2 (es) Inhibidores de monoacilglicerol lipasa (magl) de oxazina
AR109393A1 (es) Un esteroide 19-nor-c21-pirazolilo c3,3-disustituido cristalino
MX2017014809A (es) Amidas heterociclicas como inhibidores de cinasa.
CL2023000594A1 (es) Compuestos heterocíclicos
CR20160419A (es) Nuevos compuestos biciclicos
CR20160241A (es) Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infección por virus de la hepatitis b
CL2022000019A1 (es) Nuevos compuestos heterocíclicos
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación
PH12020500674A1 (en) New isoxazolyl ether derivatives as gaba a alpha5 pam
CO2022013856A2 (es) Derivados de benzodiazepinas como pam de gaba a gamma1
MX2020009022A (es) Uso de alcoxipirazoles como inhibidores de la nitrificacion.
CL2021002501A1 (es) Compuestos novedosos y métodos de uso de los mismos.
CO2021002415A2 (es) Derivados de heteroarilo bicíclicos
JOP20190159B1 (ar) توليفة من مثبط mcl-1 ومركب تاكسان، استخداماتها وتركيباتها الصيدلانية
EA201892498A1 (ru) Замещенные карбонуклеозидные производные, приемлемые в качестве противораковых агентов